Transcatheter device intervention is now offered as first line therapy for many congenital
heart defects (CHD) which were traditionally treated with cardiac surgery. While off-label use …

Cardiac septal defect is the most prevalent congenital heart disease and is typically treated
with open‐heart surgery under cardiopulmonary bypass. Since the 1990s, with the …

Shape memory biodegradable elastomers are an emergent class of biomaterials well-suited
for percutaneous cardiovascular repair requiring nonlinear elastic materials with facile …

Although the use of bioabsorbable occluder is expected to reduce the risk of metal occluder-
related complications, it has not been approved due to incomplete degradation and new …

Transcatheter intervention has been the preferred treatment for congenital structural heart
diseases by implanting occluders into the heart defect site through minimally invasive …

Background. Nowadays, transcatheter device closure of an atrial septal defect (ASD) is a
standard approach in children. Potential early and long‐term side effects or complications …

Introduction Over the last 5 years, the armamentarium of the interventional cardiologist
dealing with percutaneous closure of patent foramen ovale (PFO) has been enriched by …

Atrial septal defect (ASD) is the third most common type of structural congenital heart defect.
Patent foramen ovale (PFO) is an anatomical anomaly in up to 25% of the general …

A patent foramen ovale (PFO) persists in about one-quarter of people and is the source of up
to 25% of all ischemic strokes, especially strokes in young adults. PFO can be easily …

Fifty years ago, King and Mills performed the first percutaneous closure of atrial septal defect
(ASD) using a double-umbrella device consisting of stainless-steel struts covered with …